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Glioma is a rare, but highly fatal, cancer that accounts for the majority of malignant primary brain tumors.
Inherited predisposition to glioma has been consistently observed within non-syndromic families. Our
previous studies, which involved non-parametric and parametric linkage analyses, both yielded significant
linkage peaks on chromosome 17q. Here, we use data from next generation and Sanger sequencing to
identify familial glioma candidate genes and variants on chromosome 17q for further investigation. We
applied a filtering schema to narrow the original list of 4830 annotated variants down to 21 very rare (,0.1%
frequency), non-synonymous variants. Our findings implicate the MYO19 and KIF18B genes and rare
variants in SPAG9 and RUNDC1 as candidates worthy of further investigation. Burden testing and
functional studies are planned.
G
liomas comprise approximately 75% of all malignant primary brain tumors (PBTs) and account for an
estimated 4% of cancer deaths in the United States1–4. Glioblastoma multiforme (GBM) is the most
common type of glioma, constituting nearly 65% of cases, with an incidence rate of 2–3 per 100,000 in the
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United States and Europe. The 5-year survival for individuals with
GBM is only about 10%, and median survival time is an estimated
12–14 months.
Despite decades of research, there are few established risk fac-
tors for glioma5. A number of candidate gene and genome wide
association studies have been conducted6–10, and have, thus far,
revealed seven low-penetrant susceptibility loci associated with
sporadic glioma formation8. With regard to familial glioma,
known single gene disorders, such as neurofibromatosis, tuberous
sclerosis, and Li-Fraumeni and Turcot’s syndromes, predispose
patients to glioma formation, but cannot explain more than a
minute proportion of cases11. Therefore, the factors responsible
for first-degree relatives of glioma patients having approximately
twice the risk of glioma formation compared to unrelated indivi-
duals remains unclear12.
Because the genetic basis of familial glioma remains enigmatic, the
‘‘Genetic Epidemiology of Glioma International Consortium’’
(Gliogene Consortium) was formed in 2006 to recruit families affec-
ted by glioma in 14 different institutions across five countries11,13,14.
This consortium has provided an unprecedented opportunity to fur-
ther our understanding of the heritability of this rare, though highly
fatal, condition, with the ultimate goal of uncovering enough
information about glioma susceptibility to allow for the screening
and genetic counseling of high-risk individuals and families. Our
previous studies, which involved non-parametric and parametric
linkage analyses, both yielded significant linkage peaks only on chro-
mosome 17q (parametric linkage score: 3.1, nonparametric linkage
score: 3.39)13,15. Because of the concordance between these prior
findings, we conducted targeted sequencing focused on this region
of chromosome 17q, with the aim of identifying the variant(s) or
gene(s) that could explain linkage across this region to familial
glioma. We, additionally, characterized deleterious rare variants
within this chromosomal region among these glioma families.
Results
The linkage region was defined as the 1.7 LOD drop region from
linkage peaks, which spans bases 34,355,567-52,135,011 and
54,612,056-61,596,548 (GRCh37 coordinates) on chromosome 17
(solid bars in Fig. 1).
A total of 203 individuals from 23 families were successfully
sequenced (33 affected, 170 unaffected) to an average depth of cov-
erage of 95 fold in the target regions. Of these families, 20 had at least
one affected individual sequenced (probands of three families failed
sequencing and were subsequently excluded from additional ana-
lysis). Information on the demographics of affected individuals,
whether sequencing was completed, and the relationship between
affected individuals in each family is summarized in Table 1.
Affected individuals were not sequenced if they were deceased prior
to study initiation, or if a specimen was otherwise unobtainable.
After alignment and variant calling, a total of 4,830 variants were
annotated. After removing common variants, variants mapping out-
side our selected target regions, variants only present in unaffected
individuals, and variants not segregating among affected individuals
in the same family, there were 539 remaining variants, which were
subsequently submitted for Sanger sequencing verification for the
affected individuals (Fig. 2A). All of the variants in our final list
(Table 2) were located within the linkage region.
Sanger sequencing. Out of 539 variants interrogated by Sanger
sequencing, some failed initial design and quality checks, including
several attempts at successful primer design, in part due to the
location of the variants within high-repeat or low-complexity
regions or within duplicated regions. A total of 278 variants
(51.6%) were validated in at least in a subset of affected individuals
(Fig. 2B). Reads not meeting the aforementioned quality control
criteria were removed, leaving 186 variants (66.9%) that were fully
verified by Sanger sequencing. Our final filtering criteria were then
applied (Fig. 2B). A final list of 21 candidate variants, all missense
mutations, was obtained (Table 2).
Candidate variants. The 21 candidate variants on our final list are
each private to individual families (Table 2). There were 15 candidate
variants present in more than one affected individual per family (‘‘2/
2’’ affected ratio in Table 2), and the remaining six variants were in
families with only one sequenced affected individual. Of the 15
shared variants, three variants are novel, never having been
reported in a publicly available variant database (dbSNP, ESP,
1000 Genome Project). These include two missense mutations in
RSAD1 and MYO19 in both affected and 3 out of 8 unaffected
Figure 1 | Combined results of parametric and non-parametric linkage analysis on Gliogene families. The only significant peaks are on chromosome
17q. All coordinates are based on human genome version 19 sequence (GRCh37). Solid bars represent the linkage locus, defined as the 1.7 LOD
drop region.
www.nature.com/scientificreports
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Table 1 | Characteristics of and relationships between individuals affected by histologically-confirmed glioma in each family
Relationship Histology Age Dx Sex Sequenced
Family A
Proband Oliogdendroglioma 48 Female Yes
Sibling Astrocytoma 33 Male Yes
P 2nd Cousin Ependymoma 20 Female No
Family B
Proband Astrocytoma 40 Female Yes
P 1st Cousin Oliogendrglioma 30 Female Yes
Family C
Proband Anaplastic Astro 40 Male Yes
Sibling GBM 46 Male Yes
Sibling Astrocytoma 16 Female No
Family D
Proband GBM 54 Female Yes
Father UNK Glioma 31 Male No
P Aunt GBM 55 Female No
Family E
Proband Anaplastic Astro 39 Male Yes
Sibling Oligodendroglioma 27 Female Yes
Family F
Proband GBM 61 Male Yes
Sibling GBM 52 Female Yes
Family G
Proband Anaplastic Oligo 28 Male Yes
Father Anaplastic Astro 29 Male Yes
P Grandfather UNK Glioma 50 Male No
Family H
Proband GBM 59 Male Yes
Sibling UNK Glioma 42 Male No
Family I
Proband Anaplastic Oligo 58 Female Yes
Nephew Oligodendroglioma 32 Male Yes
Family J
Proband Anaplastic Astro 27 Female Yes
Sibling Oligoastrocytoma 38 Male Yes
Family K
Proband Anaplastic Oligo 65 Male No
M Aunt GBM 82 Female Yes
M Great Aunt GBM 79 Female No
M Great Aunt Anaplastic Astro 81 Female No
M 1st Cousin Once Removed UNK Glioma 63 Female No
M 1st Cousin Once Removed GBM 61 Male No
Family L
Proband Astrocytoma 39 Female Yes
M Aunt GBM 66 Female Yes
Family M
Proband GBM 66 Female Yes
M Aunt GBM 59 Female No
Family N
Proband GBM 66 Male Yes
Sibling GBM 53 Male No
Family O
Proband Astrocytoma 43 Female Yes
Mother UNK Glioma 27 Female No
Sibling GBM 45 Male No
Family P
Proband Anaplastic Astro 28 Male Yes
Identical Twin Oligoastrocytoma 18 Male Yes
Family Q
Proband GBM 10 Female Yes
M Grandmother GBM 65 Female No
Family R
Proband GBM 44 Female Yes
Sibling GBM 22 Male No
Niece Astrocytoma 24 Female Yes
Niece Astrocytoma 4 Female No
M Aunt UNK Glioma 11 Female No
M 1st Cousin Astrocytoma 38 Female Yes
M 2nd Cousin Once Removed UNK Glioma 49 Female No
www.nature.com/scientificreports
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members of Family J, and a missense mutation in G6PC in both
affected and 0 out of 5 unaffected members of Family A.
Although each specific variant on our final list was private to an
individual family, there were two genes for which more than one family
had variants that made the final list.MYO19 was implicated in Families
J and O, and KIF18B was implicated in Families G and B (Table 2).
Of the 21 candidate variants identified by our filtering schema, 19
had scaled C-scores above 10, indicating that these variants are pre-
dicted to be in the top 10% of the most deleterious possible substitu-
tions in the human genome. The highest scaled C-scores belonged to
SPAG9 rs143491486 (C-score: 32.0), RUNDC1 rs61995866 (C-score:
28.2), and the variant in TTC25 (chr17:40091564 C.G; C-score:
25.9). In Family L, both sequenced affected individuals and 3 out
of 4 sequenced unaffected individuals had the SPAG9 rs143491486
variant. However, 2 of the 3 unaffected individuals who had this
SPAG9 variant were children (Fig. 3a). The abbreviated CADD out-
put is provided as supplementary information.
Discussion
In this study, we attempted to identify variants on targeted regions of
chromosome 17q that could explain linkage across familial glioma
cases. We also sought to describe the distribution of potentially dele-
terious rare variants within participating glioma families. As in any
NGS study, we obtained a large list of variants and had to devise a
filtering and verification strategy to refine our list for inclusion of
only the most relevant variants (Fig. 2). Although we did not detect a
variant (or gene) that could explain linkage across all participating
families, we did identify several very rare or novel missense variants
(many of which are predicted to be in the top 10% of the most
deleterious substitutions possible in the human genome) that segre-
gated in sequenced affected members of individual families. In com-
plex diseases such as glioma, the importance of identifying
deleterious rare variants (e.g., private mutations) should not be
underestimated, as such variants may pinpoint genes that could be
important to disease pathogenesis. Furthermore, despite being infre-
Figure 2 | Chromosome 17q variant filtering schema. (a) Flowchart depicts the initial set of variant filters used to narrow the list of variants for Sanger
sequencing. ‘‘Targeted region’’ and ‘‘Linked locus’’ filters were waived for variants in Cancer Gene Census53 genes. (b) Flowchart depicts the quality check
process for Sanger-confirmed variants and the post Sanger sequencing set of variant filters applied to arrive at the final list of 21 candidate variants.
Table 1 | Continued
Relationship Histology Age Dx Sex Sequenced
M 2nd Cousin Once Removed UNK Glioma 46 Female No
P 1st Cousin Twice Removed UNK Glioma 78 Male No
P 2nd Cousin Once Removed UNK Glioma 4 Male No
Family S
Proband Oligodendroglioma 37 Female Yes
Sibling Ana Oligoastro 41 Male Yes
Family T
Proband GBM 68 Female Yes
Mother GBM 78 Female No
M Uncle UNK Glioma 49 Male No
P, Paternal; M, Maternal; Dx, Diagnosis; UNK, unknown; Ana, anaplastic; GBM, glioblastoma multiforme; Astro, astrocytoma.
www.nature.com/scientificreports
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quent in the general population, the identification of these rare var-
iants can highlight genes or genomic regions in which a series of less
deleterious and more common mutations may interact to cumula-
tively increase disease risk in a larger population.
Two interesting candidate genes identified in this study are
MYO19 andKIF18B, which were the only genes that were implicated
in more than one family.MYO19 codes for a myosin that is involved
in mitochondrial motility16. The MYO19 gene has not been well-
studied in relation to carcinogenesis; however, one study has implied
that it may act as a fusion gene in breast cancer tissues17. KIF18B
encodes a protein product that regulates microtubule dynamics (i.e.,
microtubule length) and thus, plays an important role in cell division
through its involvement in mitotic spindle assembly18–20. KIF18B has
been shown to be overexpressed in hepatocellular carcinoma, and
some evidence suggests that the expression of this gene may also be
deregulated in several other types of tumor tissues20,21. Both of these
genes warrant additional examination in future etiologic studies.
A promising candidate variant identified in our study, SPAG9
rs143491486 (p.Ser269Leu), is predicted to be among the top 0.1%
of the most deleterious variants possible in the human genome
(Table 2, Family L), based on its Combined Annotation-
Dependent Depletion22 scaled C-score of 32. The product of this
Figure 3 | (a) SPAG9(L) and (b) RUNDC1(C)mutations in familial glioma pedigrees. Individuals with glioma are shown as filled. Individuals with other
cancers are shown as half-filled. Disease and age in years (y) at first diagnosis is given underneath the symbol, current age or age at death (1)
above it. Glioma type is shown (AA, anaplastic astroctyoma; Astro, astrocytoma; GBM, glioblastoma multiforme). Other cancers in the pedigree are
shown (OvC, ovarian cancer; Mel, melanoma;TesC, testicular cancer; Lym, lymphoma). Carriers of SPAG9 (a) and RUNDC1 (b) mutations are shown
with their specific mutation, whereas individuals who tested negative for the mutation in the specific pedigree are depicted as wild-type (WT).
Table 2 | List of 21 very rare or novel missense variants within the linkage locus that segregate among all affected members of individual
families. Listed in order of the Combined Annotation-Dependent Depletion scaled C-scores22, each variant is private to one family. Families
not listed had no variants that survived filtration. The affected (or unaffected) ratio denotes the number of sequenced affected (or unaffected)
individuals carrying the variant over total number of sequenced affected (or unaffected) individuals within the family
Family
ID
Chr. 17
Position
Ref.
Allele
Var.
Allele
Gene
Symbol
ESP6500
Freq.
1000G
Freq.
dbSNP
ID
Affected
Ratio
Unaffected
Ratio
Scaled
C-Score
L 49098662 G A SPAG9 0.069% rs143491486 2/2 3/4 32.0
C 41143047 G C RUNDC1 0.069% 0.05% rs61995866 2/2 2/4 28.2
M 40091564 C G TTC25 1/1 5/8 25.9
O 34883425 G A MYO19 1/1 4/5 19.2
C 39503458 C T KRT33A 0.015% rs142400197 2/2 1/4 19.2
G 43005646 G C KIF18B 0.090% rs202002436 2/2 0/4 18.8
B 43006370 C T KIF18B 0.008% rs201865018 2/2 1/6 18.4
P 40345030 C A GHDC 0.038% 0.09% rs149568450 2/2 2/4 18.1
J 34859014 C T MYO19 2/2 3/8 17.4
P 42750898 A T C17orf104 0.05% rs192757598 2/2 2/4 16.2
A 41063291 G A G6PC 2/2 0/5 14.5
L 37785802 C A PPP1R1B rs201594054 2/2 2/4 14.1
H 38933291 G A KRT27 0.077% rs148928902 1/1 2/6 14.0
C 45904542 C T MRPL10 0.046% 0.05% rs149631185 2/2 3/4 14.0
J 48561815 T C RSAD1 2/2 3/8 12.2
S 41338453 G C NBR1 0.042% rs200709037 2/2 3/6 11.3
B 48141461 G A ITGA3 0.05% rs201210478 2/2 1/6 10.7
K 39036435 C T KRT20 1/1 0/24 10.5
J 39620632 G A KRT32 0.008% rs147094229 2/2 4/8 7.2
K 55194252 G A AKAP1 0.062% rs149147838 1/1 1/24 6.7
N 45419305 C G EFCAB13 0.038% rs138179179 1/1 4/7 5.0
www.nature.com/scientificreports
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gene, sperm-associated antigen 9 (SPAG9), is a member of a
scaffolding protein family that helps MAP-kinases bind with their
transcription factors to activate specific signal transduction path-
ways23–25. SPAG9 is actually a putative oncoprotein that has been
implicated in prostate, breast, hepatocellular, thyroid, cervical, lung,
bladder, and endometrial cancers23,24,26–34. Recently, Yi et al. showed
that SPAG9was differentially overexpressed in human astrocytomas,
compared to normal astrocytes, and that SPAG9 expression
levels were positively correlated with tumor grade (p,0.001)24.
Interestingly, in our study, one of the two sequenced affected indi-
viduals carrying the SPAG9 variant in Family L had a Grade II astro-
cytoma (Fig. 3a). Although the exact mechanism through which this
particular SPAG9 variant may be involved in gliomagenesis is
unknown, it has been suggested that the SPAG9 protein may influ-
ence cell invasion by upregulating the expression of MMP9 (matrix
metallopeptidase 9, a.k.a. gelatinase-B), which, in turn, has been
shown to be involved in the neovascularization of malignant
gliomas35,36.
The non-synonymous SPAG9 variant identified in our study con-
tributes to existing evidence that this gene may play an important
role in glioma susceptibility. This variant is predicted to be protein
damaging by SIFT (SIFT score: 0; http://sift.jcvi.org/)37 and PolyPhen
(Polymorphism Phenotyping score: 0.997)38, and is at a location that
is highly evolutionarily conserved. Ascertainment of whether cur-
rently unaffected members of Family L who carry this variant
develop glioma in the future will be extremely important, as the
unaffected individuals carrying this variant were under the age of
20 and may develop glioma later in life (Fig. 3a).
There is little known about the variant with the next highest C-
score, RUNDC1 rs61995866 (p.Glu386Gln). This variant is predicted
to be in the 1% most deleterious of all possible substitutions in the
human genome. The RUNDC1 protein has been shown by a high-
throughput RNA interference-based screening study to be a p53
regulator39,40. Interference with this gene resulted in increased p53
transcription, thus indicating that the RUNDC1 protein may be a
p53 antagonist39. However, this variant has not previously been
studied in relation to familial glioma. Both sequenced affected indi-
viduals in Family C carried this mutation, as did two of four
sequenced unaffected individuals (implying incomplete penetrance)
[Fig. 3b]. However, one of the two unaffected individuals carrying the
RUNDC1 variant was only in her early 20s at last contact.
Even the variants on our final list that have lower C-scores may
provide interesting candidates for further investigation. For example,
the candidate gene with the highest number of somatic non-silent
mutations in The Cancer Genome Atlas (TCGA) low-grade glioma
database is G6PC with three tumor samples containing missense
somatic variants, followed by one tumor sample for each of
MYO19, GHDC¸ and KRT27. Looking at the combined low-grade
glioma and glioblastoma multiforme TCGA data, G6PC remains
the gene with the highest number of somatic non-silent mutations
(four tumor samples) followed byMYO19 (three tumor samples) and
KIF18B (two tumor samples). This was based on an analysis of 279
low-grade glioma and 268 glioblastoma multiforme tumor samples
from the TCGA project as reported by the International Cancer
Genome Consortium (https://dcc.icgc.org/).
Targeted deletion of G6PC in mice leads to hepatic tumorigen-
esis41, and this gene is expressed at comparable levels in the central
nervous system according to the Cancer GenomeAnatomy Project42.
Along with the finding that both affected (with low grade glioma)
and no unaffected members of Family A carried the G6PCmissense
variant in their germline (scaled C-score: 14.5), this information
makes the G6PC variant another interesting candidate for future
study.
It is also noteworthy that four different keratin genes were impli-
cated in our final list (Table 2, Families C, H, K, and J).
Overexpression of cytokeratins has been reported in some can-
cers43–45, but little is known about the potential role of these genes
in gliomagenesis. There is a cluster of keratin-related genes or pseu-
dogenes on chromosome 17q,45 thereby obscuring whether these
findings may truly be biologically relevant or simply represent an
artifact of our loci of interest.
Glioma is a complex disease where multiple loci are likely to be
important for disease development within a family. In order to max-
imize resources, the regions targeted for sequencing in our study
were chosen strategically to ensure comprehensive coverage of what
were likely to be the most pertinent linkage regions. However, within
our sequencing targets, there are numerous regions that are notor-
iously difficult to sequence via the NGS platform and Sanger sequen-
cing, possibly due to genomic duplications or high repeat content.
Additionally, we acknowledge that other loci, outside of the regions
covered by this study, have previously been linked to familial
glioma46 (although no causative variants in these regions have been
definitively established). For example, in our other analyses, we have
found that two Gliogene families (D and R) had TP53mutations that
may help explain their increased glioma risk47. Interestingly, neither
of these families had chromosome 17q variants that met our final
filtering criteria in the current study.
One of the challenging aspects of studying diseases with high
mortality, such as glioma, is that there are very few families for which
we can obtain biologic samples from more than one or two affected
family members, which limits the possibility of performing segrega-
tion analyses of rare variants. Only about 5% of glioma patients have
a family history of glioma14, and in 83% of glioma families, there are
only two glioma patients in the family11, indicating a complex disease
with low penetrance of causal variants. Unfortunately, we were
unable to detect a variant that could explain linkage across all par-
ticipating families in this study. Because there are no established
filtering strategies for studies such as this one, we had to develop
the filtering schema presented here to maximize the potential of
finding such variants, while simultaneously excluding variants com-
mon among healthy populations.
Despite these limitations, the findings of this study may lend a
substantive amount of insight into genes involved in gliomagenesis,
and future studies should evaluate the candidate genes/regions iden-
tified here for the presence ofmore common/less deleterious variants
that may cumulatively impact familial glioma risk in a larger popu-
lation. Overall, our study complements the previous research con-
ducted by the Gliogene Consortium on the enigmatic factors
contributing to familial glioma risk. The importance of the chro-
mosome 17q region is becoming increasingly clear, though several
additional studies are necessary before definitively conclusions can
be drawn. We are currently in the process of obtaining copy number
variation (CNV) data for a subset of the Gliogene families. The CNV
datawill be examined in the context of what is currently known about
factors that predict familial glioma susceptibility in the hopes that
enough information can be amassed from the Gliogene
Consortium’s series of studies to be able to differentiate and provide
genetic counseling to high-risk families and individuals.
Methods
Study Population. Families recruited for participation in the Gliogene Consortium
had at least two biologically related members (83% of families with two and 17% with
three or more affected family members) who were diagnosed with a histologically-
confirmed glioma11. The study population and recruitment scheme have been
described in detail elsewhere11,13–15. Briefly, for the analyses presented here, the glioma
families (n523) contributing most to the linkage peaks identified in Shete et al.
(2011)13 and Sun et al. (2012)15 were selected for genomic sequencing.
Sample collection. Blood or saliva samples from glioma family members were
obtained under written informed consent at each Gliogene Consortium recruitment
center. DNA samples were prepared as previously described13. This study was
approved by the Institutional Review Board of each Gliogene institution, including
Baylor College ofMedicine, and was conducted in accordance with the Declaration of
Helsinki. Informed consent was obtained from all participants or their guardians.
www.nature.com/scientificreports
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Library construction.DNA samples were constructed into Illumina paired-end pre-
capture libraries according to the manufacturer’s protocol (Illumina
Multiplexing_SamplePrep_Guide_1005361_D) with modifications as described in
the BCM-HGSC protocol (Illumina Barcoded Paired-
End_Capture_Library_Preparation). Libraries were prepared using Beckman robotic
workstations (Biomek NXp and FXp models). Briefly, 1 ug of DNA was sheared into
fragments of approximately 300–400 base pairs with the Covaris E210 system
followed end-repair, A-tailing, and ligation of the Illuminamultiplexing PE adaptors.
Pre-capture ligation-mediated PCR (LM-PCR) was performed for 6–8 cycles of
amplification using the 2X SOLiD Library High Fidelity AmplificationMix (a custom
product manufactured by Invitrogen). Purification was performed with Agencourt
AMPure XP beads after enzymatic reactions, and following the final purification,
quantification and size distribution of the pre-capture LM-PCR product was
determined using the LabChip GX electrophoresis system (PerkinElmer).
Custom capture design. The DNA capture reagent was designed to target all coding
exons of all genes, the UTRs of cancer related genes, miRNA binding sites in all 39
UTRs, transcription factor binding sites, miRNA and small nucleolar RNAwithin the
chromosome 17 linkage peak region.
The pre-capture libraries were pooled as a 46-plex (totaling 1 ug per pool) and
hybridized in solution to the custom Gliogene capture reagent (1.6 Mb, NimbleGen)
according to the manufacturer’s protocol (NimbleGen SeqCap EZ Exome Library SR
User’s Guide) with minor revisions. Human COT1 DNA was added into the
hybridization to block repetitive genomic sequences, followed by post-capture LM-
PCR amplification using the 2X SOLiD Library High Fidelity AmplificationMix with
14 cycles of amplification. After the final AMPure XP bead purification, quantity and
size of the capture library was analyzed using the Agilent Bioanalyzer 2100DNAChip
7500. The efficiency of the capturewas evaluated by performing a qPCR-based quality
check on the enrichment level of four standard NimbleGen internal control loci.
Successful enrichment of the capture libraries was estimated to range from a 6 to 9 of
DCt value over the non-enriched samples.
Sequencing. Library templates were prepared for sequencing using Illumina’s cBot
cluster generation system with TruSeq PE Cluster Generation Kits. Briefly, these
libraries were denatured and diluted in hybridization buffer in order to achieve a load
density of ,800 K clusters/mm2. Each library pool was loaded in a single lane of a
HiSeq flow cell, with 2% phiX control library spiked into the lane for run quality
control. The sample libraries then underwent bridge amplification to form clonal
clusters, followed by hybridization with the sequencing primer. The sequencing run
was performed in paired-end mode using the Illumina HiSeq 2000 platform. Using
the TruSeq SBS Kits, sequencing-by-synthesis reactions were extended for 101 cycles
from each end, with an additional 7 cycles for the index read. With the sequencing
runs yielding an average of,838 Mb per sample, samples achieved an average of 86%
of the targeted exome bases covered to a depth of 20X or greater.
Initial sequence analysis was performed using theHGSCMercury analysis pipeline
(https://www.hgsc.bcm.edu/content/mercury)48. In summary, the .bcl files produced
on-instrument were first transferred into the HGSC analysis infrastructure by the
HiSeq Real-time Analysis module. Mercury then ran the vendor’s primary analysis
software (CASAVA) to de-multiplex pooled samples and generate sequence reads
and base-call confidence values (qualities), followed by the mapping of reads to the
GRCh37 Human reference genome (http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/human/) using the Burrows-Wheeler aligner (BWA, http://bio-bwa.
sourceforge.net/)49. The resulting BAM (binary alignment/map)50 file underwent
quality recalibration using GATK (http://www.broadinstitute.org/gatk/)51, andwhere
necessary the merging of separate sequence-event BAMs into a single sample-level
BAM. BAM sorting, duplicate read marking, and realignment to improve insertion/
deletion discovery all occur at this step.
Sanger validation.Mutation validation was performed with bidirectional sequencing
of the selected sample sites. PCR reactions were prepared using 5 ng of genomic
DNA, 0.4 mM oligonucleotide primers, and 0.7X Qiagen Multiplex Master Mix (Cat.
no. 206145) containing HotStar Taq, buffer, and polymerase. Reactions were per-
formed with and without QSOL PCR additive to enhance PCR and final sequence
performance. Touchdown PCR was performed with the following parameters: 98uC
for 5 min. and 10 cycles of 98uC for 30 sec., 72uC for 30 sec. (decreasing by 1uC per
cycle), and 72uC for 1 min. The reaction then continued with 30 cycles of 98uC for
30 sec., 63uC for 30 sec., and 72uC for 1 min, followed by a final extension at 72uC for
5 min. The PCR products were purified with a 1:15 dilution of Exo-SAP, diluted by
0.6X, and then cycle-sequenced for 25 cycles using a 1/64th dilution of BigDye
Terminator v3.1 reaction mix (Applied Biosystems, Cat. No. 4337456). Finally,
reactions were precipitated with ethanol, resuspended in 0.1 mM EDTA, and ana-
lyzed on AB 3730xl sequencing instruments using the Rapid36 run module and 3xx
base-caller. SNPs were identified using SNP Detector software and then visually
validated with Consed.
Variant annotation and filtering. Variants were annotated for functional effect on
protein and presence in variant databases (i.e., dbSNP), as well as knownminor allele
frequency using AnnoVar52. We developed a filtering schema (described below) to
evaluate the full list of variants and reduce it to a subset of variants more likely to be
etiologically relevant (i.e., very rare protein-altering candidate variants within the
linkage region).We implemented this series of filtering strategies using scripts written
in R (version 2.15.3).
Variants thatmet initial filtering criteria were verified by Sanger sequencing among
affected individuals, and an additional post-Sanger filtering strategy was then applied.
Filtering was carried out in a stepwise fashion with verification of the excluded
variants at each step to ensure that biologically significant variants were not being
eliminated.
Initial Filtering Strategy.The borders of the linkage region were defined based on a 1.7
LOD drop region (, 99% linkage confidence interval) from the linkage peaks iden-
tified in our previous two analyses13,15, which encompassed two adjacent regions on
chromosome 17q. Variants located outside this linkage region were excluded
(‘‘Linked locus’’ filter), unless the variants outside the region were in genes found in
the Cancer Gene Census (CGC)53. The CGC, which is maintained byWelcome Trust
Sanger Institute, is a catalogue of variants that have previously been implicated to
have a causal role in oncogenesis. At the time of this analysis, the following 23 genes
on chromosome 17were included in the CGC:TAF15, SUZ12, LASP1, CLTC, CDK12,
NF1, RARA, BRCA1, DDX5, ETV4, MLLT6, ERBB2, COL1A1, BRIP1, HLF, CD79B,
MSI2, PRKAR1A, MSF, ASPSCR1, CANT1, SRSF2, and ALO17.
Among non-CGC genes, variants that were not within 200 bases of the sequencing
target regions were excluded (‘‘Targeted Region’’ filter). Next, common variants,
defined as those that had.5% frequency in the Exome Sequencing Project (ESP5400
release)54 or 1000 Genome (1000G, 2010_07 release)55 CEU population, were also
excluded (‘‘Rare Variant’’ filter). Finally, we removed any variant that was not shared
by all sequenced affected individuals of at least one family, prior to Sanger verification
(‘‘Family Segregation’’ filter).
Post-Sanger Filtering Strategy. Variants were considered verified if Sanger reads had
full concordance with NGS reads in all affected individuals, and both the forward and
reverse reads agreed. Final filtering involved excluding the following: variants outside
of the linkage region (‘‘Linked locus’’ filter); variants with a minor allele frequency
.0.1% in the ESP6500 release or 1000G 2012_04 release (‘‘Very Rare Variant’’ filter);
variants not within the exonic sequencing target regions (‘‘Targeted Exome’’ filter);
and variants that did not alter the amino acid sequence of the product protein
(‘‘Protein Alteration’’ filter). The aim of this filtering strategy was to narrow down the
list of variants to a list of very rare protein-altering candidate variants within our
linkage locus. This was, however, carried out in a step-wise fashionwith verification of
the excluded variants at each step for potential biological function to ensure we are
not excluding any biologically significant variants.
Combined Annotation-Dependent Depletion C-Score. After implementing the
above filtering schema, we used scaled C-scores from the Combined Annotation-
Dependent Depletion (CADD) method to rank the variants remaining on our
final list by potential deleteriousness22. The CADD C-score provides an integ-
ration of 63 different annotations (i.e., allelic diversity, functionality, putative
pathogenicity, and evolutionary conservation) into one score per variant. For
example, the C-score integrates scores from PolyPhen38 and SIFT37 for predicted
impact of the variant on protein function, GERP56 and PhyloP57 for evolutionary
conservation, and a number of other annotations for prioritization of causal
variants22. A scaled C-score $10 indicates variants predicted to be in the top 10%
of the most deleterious possible substitutions in the human genome, a score of
$20 indicates variants predicted to be in the top 1%, and a score of $30 indicates
variants predicted to be in the top 0.1%. More details on the CADD C-score can
be found elsewhere22.
Ethics.Written informed consent was obtained from each subject or from his or her
guardian. Approval from local institutional review boards was received at each
Gliogene participating institution. This study was conducted in accordance with the
Declaration of Helsinki.
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